Quick Answer
TEVA PHARMACEUTICAL INDUSTRIES LTD reported Net Income Loss of $1.41 billion for the year ending 2025.
- TEVA PHARMACEUTICAL INDUSTRIES LTD showed an increase of +186.0% in Net Income Loss from 2024 to 2025.
- This data is from TEVA PHARMACEUTICAL INDUSTRIES LTD's annual report (Form 10-K), filed with the SEC on February 3, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 18 years of available data (2008 to 2025), TEVA PHARMACEUTICAL INDUSTRIES LTD's Net Income Loss has grown by 131.5%.
- Historical annual values: Fiscal year 2025: $1.41 billion | Fiscal year 2024: -$1.64 billion | Fiscal year 2023: -$559.00 million | Fiscal year 2022: -$2.45 billion | Fiscal year 2021: $417.00 million | Fiscal year 2020: -$3.99 billion | Fiscal year 2019: -$999.00 million | Fiscal year 2018: -$2.15 billion | Fiscal year 2017: -$16.27 billion | Fiscal year 2016: $329.00 million | Fiscal year 2015: $1.59 billion | Fiscal year 2014: $3.06 billion | Fiscal year 2013: $1.27 billion | Fiscal year 2012: $1.96 billion | Fiscal year 2011: $2.76 billion | Fiscal year 2010: $3.33 billion | Fiscal year 2009: $2.00 billion | Fiscal year 2008: $609.00 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: